[View original text]

On 8th of February, AIDOT announced that it has signed a 3-year, $20 million contract to supply ‘Cerviray AI’ with CerviQ in the Philippines.

CerviQ is a company specializing in cervical cancer screening, established in 2014 by a local obstetrician in the Philippines.

The company applied Pap Smear Cytology (cytology), HPV-DNA test, and VIA (Visual Inspection with Acetic Acid) methods to the tests, but there were limitations in conducting 

cervical cancer tests smoothly in the Philippines, which is made up of about 7,000 islands. In addition, it was difficult to spread the test due to the lack of specialized doctors and 

cytology equipment.

On the other hand, cervical cancer ranked first among female cancers in the Philippines, so the need for screening was high.

CerviQ solved this problem with the introduction of AIDOT's Cerviray AI, a VIA method.

Cerviray AI can perform cervical cancer screening in a mobile vehicle, and can also be tested on islands with Cerviray AI's own colposcopy equipment.

In addition, with an artificial intelligence reading rate of 93%, it is evaluated to be very efficient for pre-screening for cervical cancer in Filipino women.

AIDOT decided to produce and supply its own equipment from the existing Swedish Colposcope equipment, completed the development of its own camera, and is working on molds 

for mass production.

Accordingly, AIDOT expects to be able to start supplying AI-based examination solutions at the end of March, including its own colposcope equipment, to domestic and foreign 

partners, including the Philippines.

Aidot has obtained ISO13485 and European CE certification, and has also completed KFDA3 level for export and GMP certification. Currently, domestic KFDA certification is in 

progress.

AIDOT CEO Jae-hoon Jeong said, “AIDOT is the only AI-based medical ICT company in Korea that has grown only through national government research projects and achieved exports, and if this year’s target export amount of 10 billion won is achieved without difficulty, we are considering going public around 2022.”

08th. Feb. 2021. / Korea Economy TV / Reporter Seon-yeop Kim sykim@wowtv.co.kr

<Copyright holder © Medical Device Newsline Unauthorized reproduction and redistribution prohibited>